June 16th 2022, 4:24pm
Aaron T. Gerds, MD, MS, discusses the clinical trial development of momelotinib, a JAK1/JAK2 inhibitor that is being investigated for the treatment of patients with myelofibrosis.
June 8th 2022, 2:00pm
The addition of zanubrutinib to obinutuzumab in patients with relapsed/refractory follicular lymphoma demonstrated improved overall response rates, progression-free survival, and overall survival.
June 8th 2022, 1:00pm
Rivoceranib showed promising responses in regard to objective response rate and disease control rate when used in patients with recurrent or metastatic adenoid cystic carcinoma.
June 8th 2022, 12:27am
Dostarlimab monotherapy induced durable antitumor activity in advanced or recurrent endometrial cancer among patients with mismatch repair deficient/microsatellite instability–high or mismatch repair proficient/mismatch stable disease, according to data from 2 expansion cohorts in the GARNET trial.
June 7th 2022, 6:20pm
At the 2022 ASCO Annual Meeting, utilizing matching-adjusted indirect comparison, researchers showed the survival benefit of larotrectinib in patients with TRK fusion-positive tumors.
June 7th 2022, 5:54pm
Selinexor has demonstrated improvement in progression-free survival over placebo in patients with advanced or recurrent endometrial cancer.
June 7th 2022, 3:24pm
Reduced risk of metastatic progression and improved overall survival seen with darolutamide in patients with nonmetastatic castration-resistant prostate cancer.
June 7th 2022, 2:05pm
FOLFOXIRI plus panitumumab should not be recommended as upfront therapy for RAS and BRAF wild-type mCRC patients. according to investigators of the phase 3 TRIPLETE study.
June 7th 2022, 1:16pm
According to Timothy J. Whelan, MD, FASCO, radiotherapy is an inconvenient treatment. It can last daily for up to 5 weeks and it is a costly therapy. Study results shows that is can safely be omitted in the treatment of some patients with luminal A breast cancers.
June 7th 2022, 1:07pm
Phase 3 CAIRO5 showed improvements in progression-free survival and overall response with FOLFOXIRI plus bevacizumab in colorectal cancer liver metastases, but the combination demonstrated a toxic safety profile.